Ministries & Departments

National Institute of Immunohaemotology (NIIH), Mumbai

National Institute of Immunohaemotology (NIIH) is a premiere research institute of ICMR focusing on basic and translational research in the area of hematology, transfusion medicine and immunology. The thrust areas of institute include transfusion medicine, hemoglobinopathies and red cell enzymopathies, hemostasis and thrombosis, primary immunodeficiency diseases, autoimmune diseases, inherited and acquired marrow failure syndromes, hematological malignancies and transfusion transmitted diseases. At NIIH, research activities integrate both basic and clinical research to understand pathophysiology of various inherited and acquired hematological and immunological disorders and utilize the knowledge for better management and prevention of such disorders. NIIH aspire to encompass academic and research collaborations with institutes within and outside India. Institute also provides services for comprehensive diagnosis and genetic counselling of the families affected with inherited diseases including prenatal diagnostic services and focuses on developing simple cost-effective technologies for diagnosis and management of various immunohematological disorders.

Research Areas: Medical Sciences

Ministries: Indian Council of Medical Research (ICMR), Govt of India

Contact Name: Dr. Manisha Madkaikar, Director

Contact Address: National Institute of Immunohaemotology (NIIH),13th Floor, New Multistoreyed Building, KEM Hospital Campus, Parel, Mumbai, Maharashtra 400012

Contact Phone: 91 022 24132928, 24111161


Fax: 22 24138521

State: Maharashtra

Output & Achievements

  • 1. Patents [Received 02 patents (Patent No.2085/MUM/2015 and No. 194149), 02 patents filed, 01 under review, and applied for 05 patents]. 2. Books/Monographs/ Proceedings [21]. 3. Scientific Paper [>604]. 4. BGRC News Letter [74]. 5. ICMR- NIIH Training Programme for MD and DM in Haematology and Transfusion Medicine. 6. Immunohaematology Bulletin [122]. 7. IIH Scientific Papers (1952-2006) [981]. 8. Computer and IT Services. 9. Animal Care Facility (ACF). 10. Instruments: Flow Cytometer, Real-Time PCR, Nephelometer, Elispot Reader and DNA Sequencer. 11. Discoveries and Innovations [40]. • Discovery of “Bombay” blood group. • Discovery of novel LDH variant in association with HBsAg. • Discovery of Indian (Inª) blood group. • Detection of rare antigens like M g, I-i-, Ry, Rz alleles, Co(a-b-), homozygous D. • Detection of novel and rare hemoglobin variants like Hb D- Agri, HbM- Ratnagiri respectively. • Detection of several novel and rare β-thalassemia mutations. • First case of vitamin K dependent coagulation factors deficiency from India . • Protective effect of EACA (Epsilon Amino Caproic Acid) on factor VIII inhibitor dependent destruction of factor VIII. • Detection of novel mutations in Glanzmann’s thrombasthenia. • Correlation between chronic synovitis and HLA B 27 in patients with severe hemophilia. • Gene mapping of new marker chromosome using FISH. • Novel translocation in MDS ( Myelo Dysplastic Syndrome ). • Novel HLA alleles in patients with seronegative spondarthritis, hemophilia and leprosy. • HLA association with ANCA (Anti Neutrophil Cytoplasmic Antibodies) patients. • Identified several novel mutations causing coagulation factor deficiencies (factor IX, factor VII, factor X) and protein C gene. • Development of an ELISA assay for factor VIII antibody. • Development of ELISA for identification of weaker variants of A and B. • Development of ELISAs for C1q, ANA, anti-id, anti-Histone antibodies. • Strong association of microparticles of tissue factor and endothelial cell origin with unexplained recurrent pregnancy loss. • Microparticles as predictive markers for monitoring anticoagulant therapy in patients with unexplained pregnancy loss. • A simple clot based assay for detecting procoagulant microparticles. The in-house test measures the clotting time after the addition of calcium chloride to microparticle rich plasma, following incubation with Russell viper venom and phospholipid free plasma. • Microparticles as predictive biomarkers for preeclampsia and IUGR. • A specific and sensitive APTT based inhibitor screening assay using purified factor concentrate. • Large F8 gene rearrangements and IL10 promoter polymorphisms as strong risk factors for inhibitor development in Indian hemophilia A patients • A nationwide survey of hemophilia patients for inhibitors; An overall prevalence of 7.92% with wide regional variation. • Mutation profile of hemophilia A, hemophilia, B , VWD, Bernard Soulier syndrome, Glanzmanns thrombasthenia and all the rare coagulation factor deficiencies • Dengue virus preferentially infects megakaryocytic colony forming cells. Development of a cell based model for dengue virus infection. • A quick mismatched RFLP technique for detecting the founder mutation in mild to moderately deficient hemophilia B cases from Gujarat. • Demonstration that clinical severity of haemophilia due to severe disease causing mutation is modulated by co-inherited thrombophilia genes . • New clinical classification of severe hemophilia based on thromboelastogrphy. • A strong association of HLAB27 with chronic haemophilic synovitis. • Unusual association of factor V Leiden with Budd Chiari Syndrome. • Human platelet antigen genotype profile in Indian population and its application in neonatal alloimmune thrombocytopenia (NAITP). • Development of CRDB kit for detection of common beta thalassemia mutations in India.Participated in "Medical Science and Biotechnology Innovation Exhibition" at Rashtrapati Bhawan , New Delhi on 11th March 2015 and displayed the RDB kit. • Rapid Flow cytometric prenatal diagnosis of primary immunodeficiency (PID) disorders • A simple clot based assay for detection of procoagulant cell-derived microparticles. • Phenotypic Prenatal Diagnosis of Chronic Granulomatous Disease: A Useful Tool in the Absence Of Molecular Diagnosis. • Concentration of NADH-cytochrome b5 reductase in erythrocytes of normal and methemoglobinemic individuals measured by Microplate Reader. • Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. • A specific and sensitive activated partial thromboplastin time (APTT)-based factor VIII inhibitor screening assay 12. Degrees awarded: 54 (Ph.D) and 44 master’s awards. 13. International Collaboration [25]. 14. International Recognition [06].

Related links